ライフサイエンスコーパス: for treating

1 et of CD4(+) Th cells, is a promising target for treating a host of autoimmune diseases.

2 throughout the world as traditional medicine for treating a variety of diseases ranging from cancer t

3 onse and thus could be an appealing strategy for treating a variety of neurodegenerative diseases, in

4 ogies and assess their therapeutic potential for treating a wide range of diseases caused by abnormal

5 erscoring its unique translational potential for treating a wide range of pathologies caused by imbal

6 rmulations are approved in the United States for treating acute bacterial skin and skin structure inf

7 This strategy may also hold promise for treating acute hyperinflammation, such as observed i

8 Historically, the gold standard for treating acute uncomplicated type B aortic dissectio

9 tal cues with drug experiences holds promise for treating addiction, yet accessing the distributed ne

10 ential of PDAC and may prove to be effective for treating advanced disease.

11 ting PLK1-FOXO1 pathways as a novel approach for treating advanced PCa.

12 y represent a promising therapeutic approach for treating AH.

13 Here we identify disulfiram, a drug for treating alcohol addiction, as an inhibitor of pore

14 Animal studies suggest that one strategy for treating Alzheimer disease and related tauopathies m

15 ron overload in humans, offer a new approach for treating ANCL.

16 al of kappa-opioid receptor (KOR) antagonism for treating anhedonia with a POM study determining whet

17 ective inhibition of CysLT(1)R has been used for treating asthma and associated diseases for over two

18 ing SMC may represent a translational target for treating atherosclerosis.

19 ow that clinically relevant antagonists used for treating autoimmune conditions can be converted into

20 e insight in the potential of PAD inhibition for treating autoimmune diseases like type 1 diabetes.

21 unity and is considered an attractive target for treating autoimmune diseases.

22 or the development of new therapeutic agents for treating autoimmune diseases.

23 ted immunotherapies are clinically effective for treating B cell malignancies but also cause a high i

24 mour antigens, such as TAAs and neoantigens, for treating B cell malignancies.

25 maturation, could be an efficacious strategy for treating B-cell malignancies.

26 toll-like-receptor-7 agonist currently used for treating basal cell carcinoma.

27 pounds but also mixtures of natural products for treating biofilm infections and underlines the impor

28 Pharmacological options for treating bipolar disorder have increased over the pa

29 to prevent bleeding is the ultimate question for treating bleeding disorders.

30 cted in the tissue engineering of periosteum for treating bone defects.

31 us, this study provides a potential strategy for treating bone resorption in patients with myeloma by

32 d help to identify novel therapeutic targets for treating both absence seizures and their comorbiditi

33 nt and prospective pharmacological therapies for treating both EDS and cataplexy, discusses concerns

34 a-particle radiation is a promising approach for treating both large and micrometastatic lesions.

35 somes and has shown promise as a nanocarrier for treating brain diseases.

36 rrier (BBB) presents a significant challenge for treating brain disorders.

37 desired miRNAs or proteins are likely useful for treating brain injury and neurogenerative diseases.

38 plications of in vivo neuroepigenome editing for treating brain pathology.

39 er strategy and a potential therapy paradigm for treating BRCA-proficient cancers like NSCLC.

40 as emerged as an alternative to open surgery for treating cAAA, but direct comparisons are limited.

41 g that TCMCB07 is a promising drug candidate for treating cachexia.

42 e development of more potent TEAD inhibitors for treating cancer and other hyperproliferative patholo

43 the mitochondrial assembly receptor (MasR), for treating cancer cachexia.

44 creased use of targeted radionuclide therapy for treating cancer comes the increased risk of radiatio

45 ion of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy.

46 that modify the epigenome are powerful tools for treating cancer, but these drugs often have pleiotro

47 rapy has become a powerful clinical strategy for treating cancer.

48 a inhibition of CD73 is a potential strategy for treating cancers.

49 first time that ASOs may be a viable option for treating cardiac pathology in DM1.

50 Phosphodiesterase 5A1 (PDE5) is a key target for treating cardiovascular diseases and erectile dysfun

51 robial communities as a therapeutic approach for treating CD.

52 d quick supplement to the current approaches for treating CDI.

53 therapy mediated by AAV vectors can be used for treating CDKL5 disorder.

54 , and may, in our view, be a better strategy for treating certain locally advanced tumors.

55 ith senolytics is a potential novel strategy for treating cGVHD-affected LGs.

56 therapeutic properties over noncovalent ones for treating challenging diseases.

57 of let-7 function may be an effective method for treating CHD7 deficiency.

58 ith the Trab360 device is effective and safe for treating childhood glaucomas, especially PCG.

59 OST in Germany is an effective setting both for treating chronic HCV infections and for preventing n

60 confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection a

61 Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection.

62 confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and

63 a rich source of macrophage progenitors used for treating chronic inflammation and produce essential

64 r helminth-derived products may hold promise for treating chronic inflammatory-associated diseases (C

65 Of 39 NDAs approved for treating chronic pain, only 21 products were support

66 tinic acetylcholine receptor (nAChR) ligands for treating chronic pain.

67 ow subthreshold laser was safe and effective for treating CI-DME patients with good VA in this case s

68 parenchyma have been proposed as an approach for treating CKD.

69 therapeutic intervention may pave a new road for treating CNS injuries.

70 (MRgFUS) is a promising non-invasive method for treating CNS tumours.

71 , but to date no market-approved medications for treating cocaine addiction or relapse exist, and eff

72 o develop pharmacological and gene therapies for treating cocaine use disorders.

73 rates in MS, such treatments are ineffective for treating cognitive dysfunction.

74 Current methods for treating combustion exhaust include the catalytic co

75 be included, procedures had to be important for treating common conditions, well-defined, and impact

76 s a non-beta-lactam beta-lactamase inhibitor for treating complicated urinary tract and respiratory i

77 lexes and could provide a therapeutic target for treating complications from ischemic injuries.

78 HP.B's neurotrophic properties are plausible for treating conditions where the central nervous system

79 nd thymocytes, and offer practical prospects for treating congenital and acquired immunological disea

80 e efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is curr

81 tional repurposing of the existing medicines for treating COVID-19.

82 r views regarding use of convalescent plasma for treating COVID-19.

83 eceptor antagonist, eplerenone, is effective for treating CSCR; however, this drug is not licensed fo

84 Miltefosine is an FDA approved oral drug for treating cutaneous and visceral leishmaniasis.

85 geting of EndMT may hold therapeutic promise for treating CVD.

86 a locally administered drug delivery system for treating DCIS, for which no primary chemotherapy opt

87 rapidly, with novel methods and innovations for treating depression, as well as a new clinical indic

88 f bioactive lipids, which show great promise for treating diabetes and inflammatory diseases.

89 ed CD34(+) stem cell therapeutic development for treating diabetic wounds by defining their cellular

90 scopy is a novel, safe, and effective method for treating different gastrointestinal conditions.

91 ivation and reveal novel therapeutic targets for treating DIPG tumors.

92 ompounds thus have potential as therapeutics for treating disease driven by elevated cAMP signaling a

93 ic platforms, i.e., bioelectronic medicines, for treating disease states, accelerating wound healing

94 Cell and gene therapies offer opportunities for treating disease with potential to restore function,

95 st offering new pharmacological intervention for treating diseases caused by excessive FGF23 abundanc

96 nd between different tissues will be crucial for treating diseases in which type 2 immunity is an imp

97 le to pharmacologically prime the proteasome for treating diseases with IPTS.

98 ction may represent a new therapeutic target for treating disordered energy metabolism metabolic synd

99 C1 may help researchers to devise strategies for treating disorders of the nervous system involving a

100 that RNA-targeting Cas9 is a viable strategy for treating DM1 and other MRE-associated diseases.

101 of endogenous utrophin offers great promise for treating DMD, as it can functionally compensate for

102 approaches to induce therapeutic hypothermia for treating drug-resistant fever, and for improving glu

103 prioritized as a novel candidate drug target for treating dyslipidemia and associated CVD.

104 cle health and may yield therapeutic targets for treating dystrophic muscle symptoms.

105 development of new therapeutic interventions for treating EBV-associated lymphomas.IMPORTANCE Epstein

106 anscriptional programs as vulnerable targets for treating endocrine-resistant and metastatic breast c

107 Neurotrophic factors are candidates for treating epilepsy, but their development has been ha

108 bexarotene, is ineffective as a single agent for treating epithelial cancers and induces hypertriglyc

109 Therapy protocols for treating extracorporeal membrane oxygenation-associa

110 able collagen membrane to be a viable option for treating furcation-involved teeth if the defect morp

111 ptor, which is a clinically validated target for treating gastrointestinal stromal tumors.

112 form for effective topical delivery of siRNA for treating genetic skin diseases.

113 ntially serve as a powerful therapeutic tool for treating glioma.

114 active pharmaceutical ingredient widely used for treating gout, pericarditis, and familial Mediterran

115 no new antibiotic classes have been approved for treating Gram-negative pathogens in decades.

116 F on the gut microbiome suggests new avenues for treating GWI through dietary intervention.

117 y also implicates LGR4 as a potential target for treating hair disorder in the future.

118 esent MTR4 as a promising therapeutic target for treating HCC.

119 pamine signaling and represent novel targets for treating HD.

120 MR activity may provide an improved approach for treating heart disease.

121 activity may provide an additional approach for treating heart failure and reduce the risk for sudde

122 l could be a promising dual target inhibitor for treating hematologic malignancies.

123 gets rapidly and to repurpose approved drugs for treating heterogeneous diseases by the 'precise' tar

124 Cell therapy efforts for treating HIV+ patients are challenged by limited ava

125 sis of an analogue of efavirenz, a drug used for treating HIV.

126 xamples and highlighting novel opportunities for treating human cancer.

127 e potential of altering chromosome structure for treating human disease.

128 s a pathway to inhibit CaMKK2 with potential for treating human diseases.

129 A promising new compound class for treating human malaria is the imidazolopiperazines (

130 r P2X1 have potential as antithrombotics and for treating hyperactive bladder and inflammation.

131 These results provide new molecular clues for treating hyperexcitability of hippocampal circuits a

132 ysiology and identification of novel targets for treating hyperglycemia.

133 y therefore represent an attractive approach for treating hyperphosphatemic conditions.

134 (Ca(v)1.2) blockers (LCCBs) are major drugs for treating hypertension, the preeminent risk factor fo

135 ulating (ACE2u) activity, an emerging target for treating hypertension.

136 n of nanobody antagonists may provide a path for treating hypertensive disorders when small-molecule

137 One approach for treating hypertriglyceridemia may be to increase the

138 s, FABP5 is potentially a therapeutic target for treating ILC2-mediated allergic lung inflammation.

139 We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.

140 apeutically targeting JAKs as a new strategy for treating immune and inflammatory diseases.

141 pies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated admi

142 ced ATP release, which may have implications for treating impaired vascular control with advancing ag

143 zation may be a potential therapeutic option for treating individuals suffering from cutaneous leishm

144 ted an efficient PEC air-purification filter for treating indoor polluted air under ambient condition

145 ocatalytic process may be a promising method for treating industrial wastewater and producing clean e

146 ation of genes with therapeutic applications for treating infectious, inflammatory, and autoimmune di

147 ent of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without t

148 While the number of therapeutic options for treating inflammatory bowel diseases (IBD) is increa

149 aloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections.

150 Baloxavir marboxil, 4, is approved for treating influenza virus infections.

151 training that may become therapeutic targets for treating insulin resistance, in particular, the tran

152 ayer expansion, which may reveal new targets for treating intestinal fibrosis.

153 le antifungals are vital therapeutic options for treating invasive mycotic infections.

154 ction of Rg3, provided an effective strategy for treating ischemic diseases and oxidative stress and

155 etwork distribution, which may be beneficial for treating ischemic diseases.

156 model may help identify therapeutic targets for treating kidney diseases featuring molecular defects

157 s and enable the clinical application of Ade for treating large bone defects.

158 ically approved drug only being locally-used for treating liver cancer.

159 progress in the discovery of new approaches for treating lung cancer.

160 rapy may offer a potential clinical strategy for treating m-oligodendroglioma.

161 of ketamine relevant to its therapeutic use for treating major depression.

162 l-D-aspartate receptor antagonist, ketamine, for treating major depressive disorder (MDD); however, i

163 f sperm and have potential therapeutic value for treating male infertility, which afflicts >100 milli

164 es, offering a novel therapeutic opportunity for treating male infertility.

165 merging as one of the most effective methods for treating many cancers.

166 on" may be an effective therapeutic approach for treating MCL and overcoming ibrutinib resistance, th

167 provide guidance on the use of cannabinoids for treating mental disorders within a regulatory framew

168 al endurance and are suggested as candidates for treating metabolic diseases.

169 ell-tolerated alkaloid Berberine (BRB), used for treating metabolic disorders, were studied on ex-viv

170 sts targeting DNMT3B induction as new option for treating metastatic disease.

171 gnaling axis provides an attractive approach for treating metastatic diseases.

172 imus are inhibitors of mTOR (mTORi) approved for treating metastatic renal cell carcinoma (mRCC).

173 of these processes could uncover new targets for treating microbiome-mediated inflammatory diseases.

174 Topical therapies remain the cornerstone for treating mild psoriasis.

175 kimab may represent a new therapeutic option for treating moderate-to-severe HS.

176 rently, gene therapy offers a novel approach for treating monogenetic disorders, including nuclear ge

177 romodulation technologies hold great promise for treating mood and other brain disorders in next-gene

178 lar stimulation may provide a novel strategy for treating motor symptoms of degenerative cerebellar a

179 as well as informing therapeutic approaches for treating movement disorders.

180 Efforts to develop antiviral strategies for treating MS are underway.

181 gnitive rehabilitation and exercise training for treating MS-related cognitive impairment.

182 have been identified as possible candidates for treating MS-related cognitive impairment; however, c

183 polarization toward M2 is a general benefit for treating MS.

184 line and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR TB);

185 line and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB);

186 a therapeutic modality that holds potential for treating multiple chronic pathologies and extending

187 py is a promising immunotherapeutic strategy for treating multiple refractory blood cancers, but furt

188 Y720), an FDA-approved immunomodulatory drug for treating multiple sclerosis, is an agonist of sphing

189 f DGAT2 inhibitors as a therapeutic strategy for treating NAFLD and preventing downstream consequence

190 the liver may be a novel therapeutic avenue for treating NAFLD.

191 brain, suggesting them as a potential target for treating negative emotional states in mood-related d

192 e composition of ADEVs are likely beneficial for treating neurodegenerative diseases.

193 Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders, inflammation,

194 of the adult brain may be a useful strategy for treating neurological diseases.

195 ycerol Lipase (hMGL) offers a novel approach for treating neurological diseases.

196 rophic factors may offer therapeutic promise for treating neuromuscular diseases.

197 re neurotransmitter inhibitors that are used for treating neuromuscular disorders and are classified

198 type 2 diabetes, was successfully repurposed for treating neutropenia and neutrophil dysfunction in t

199 Its translational potential for treating non-genetic pathologies is still unexplored

200 ncludes the light component and the protocol for treating non-muscle invasive bladder cancer.

201 Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis

202 ly being recognized as an important strategy for treating nonparoxysmal AF.

203 tion complex and shows therapeutic potential for treating Notch-driven cancers.

204 almitoylation cycle is an appealing strategy for treating NRAS mutant cancers, particularly as normal

205 m of activity and potential utility of P2-6R for treating NSCLC and other solid tumors.

206 e developed as a potential therapeutic agent for treating OA.

207 itions and is a potential therapeutic target for treating obese breast cancer patients.

208 need to develop novel therapeutic approaches for treating obese patients.

209 DJBL is an endoscopic device for treating obesity and related disorders.

210 o promote identification of new drug targets for treating obesity and related metabolic diseases.

211 Multiple surgical targets for treating obsessive-compulsive disorder with deep bra

212 a platform on which to develop interventions for treating opioid addiction.

213 ential of targeting the PVT->NAc->LH pathway for treating opioid addiction.

214 ne-naloxone with extended-release naltrexone for treating opioid use disorder.

215 potentially safe and effective new approach for treating or preventing acute thrombotic and thromboe

216 erative disorders, is an attractive strategy for treating or preventing these diseases.

217 are likely to be potentially unique targets for treating other diseases as well.

218 (NSAIDs), the medications most commonly used for treating pain and inflammation, are the main trigger

219 hey are also pertinent to the use of opioids for treating pain resulting from traumas involving physi

220 irritant sensor and is a therapeutic target for treating pain, itch, and respiratory diseases.

221 -549 NP delivery could be a promising method for treating pancreatic cancer and other immune-suppress

222 could represent a novel therapeutic strategy for treating pancreatic cancer.

223 review on surgical reconstructive approaches for treating papillary deficiency associated with soft a

224 rapies have long been an attractive prospect for treating Parkinson disease.

225 f environmental cold and an important target for treating pathological cold hypersensitivity.

226 chnology has emerged as a promising platform for treating pathologies ranging from neuropathic pain t

227 ation is safe, it may have potential utility for treating patients with ADPKD.

228 validated and critically important approach for treating patients with cancer.

229 Resistance to chemotherapy is a major hurdle for treating patients with cancer.

230 Cryotherapy is standard practice for treating patients with cervical precancer in see-and

231 To develop a lytic-induction therapy for treating patients with EBV-associated cancers, we ne

232 helpful as part of a lytic-induction therapy for treating patients with EBV-positive malignancies tha

233 mine metabolism may be an effective approach for treating patients with PIK3CA-mutant colorectal canc

234 ot support the use of an MRI-guided strategy for treating patients with RA.

235 provides the first in vivo clinical support for treating patients with SLE with an IRF5 inhibitor.

236 rwhelming benefit of mechanical thrombectomy for treating patients with stroke caused by large vessel

237 improve the body's natural repair mechanisms for treating patients with wound-closure pathologies.

238 , cell therapy has emerged as a novel method for treating pediatric heart failure with several ongoin

239 ere the last among this group to be approved for treating people living with HIV, they have since ris

240 while UV-sulfite treatment can be effective for treating PFOS and PFOA to meet health advisory level

241 Liposomal amphotericin B and MIL combination for treating PKDL is efficacious and safe, with high tol

242 sing liposomal amphotericin B (LAmB) and MIL for treating PKDL.

243 rous antimicrobials are considered effective for treating plague; however, well-defined information o

244 tent, stress-associated memories is relevant for treating posttraumatic stress disorder (PTSD) and re

245 in concert with AR inhibition may be useful for treating prostate cancers with alterations in WNT pa

246 hanistic insights and therapeutic approaches for treating psychiatric disease.

247 study demonstrates a translational framework for treating rapidly evolving tumors through preclinical

248 ta transplantation (FMT) is highly effective for treating recurrent Clostridium difficile infection (

249 such a curve using data from a recent study for treating renal cell carcinoma.

250 elp guide the design of cell-based therapies for treating retinal dystrophies.

251 iology and identify a new therapeutic target for treating Rett syndrome.

252 is an anti-inflammatory drug primarily used for treating rheumatoid arthritis (RA).

253 d hyperplasia is a safe and effective method for treating secondary hyperparathyroidism.

254 ing such as venetoclax may prove efficacious for treating SEMA7A(+) tumors.

255 This study underscores the need for treating sex as a biological variable.

256 ociated with another biomaterial may be used for treating single or multiple GR.

257 aling has potential therapeutic applications for treating skeletal muscle atrophy.

258 that AAV-Slc25a46 could be a novel approach for treating SLC25A46-related mitochondrial disorders.

259 circadian rhythms and are important targets for treating sleep and mood disorders, type-2 diabetes a

260 degenerative diseases, and can be harnessed for treating some cancers.

261 type 2 inflammation has provided a new model for treating some patients with corticosteroid refractor

262 Immunotherapy is a powerful new approach for treating some refractory cancers; applying this 'fou

263 The optimal treatment strategy for treating ST-segment-elevation myocardial infarction

264 , thereby providing combinatorial strategies for treating stimulant abuse.

265 These promising results make IFGEM suitable for treating stormwater runoff, wastewater effluent, and

266 modulation may offer a therapeutic approach for treating such diseases.

267 ions, demonstrating a significant preference for treating such indications over non-mental health ind

268 lockade may be a viable therapeutic strategy for treating such patients.

269 Electron beam therapy (EBT) is commonly used for treating superficial and subdermal tumors.

270 using ceftazidime or piperacillin-tazobactam for treating susceptible infection.

271 stic treatment as a novel therapeutic avenue for treating T2DM.

272 s and can be developed as a targeted therapy for treating Th17 cell mediated conditions.

273 on will help find a novel therapeutic target for treating Th17 cell-mediated diseases.

274 at the pure compound may be a drug candidate for treating the accelerated and deteriorated type of lu

275 novel virus-targeted therapeutic strategies for treating the devastating human cancers associated wi

276 ential for viral replication and are targets for treating the disease COVID-19.

277 ue injury and identifying new immune targets for treating thermal injury.

278 Current therapeutic options for treating these diseases include antiangiogenic strat

279 id synthesis might provide a useful strategy for treating these disorders.

280 represents a potential therapeutic approach for treating these GSDs.

281 and leukemia cells exhibit clinical efficacy for treating these malignancies, but also attack normal

282 ctive targeting of the mutant would be ideal for treating these pathologies by sparing essential JAK2

283 nistration (FDA)-approved products available for treating these patients, and a third product is expe

284 its translational and therapeutic potential for treating this disorder.

285 ive transmission and suggests new strategies for treating this painful condition.

286 patient-specific MGE cell grafting approach for treating TLE.

287 otch pathway may be a new therapeutic target for treating TMJ osteoarthritis.

288 bilities, which points to a promising target for treating transport disorders and improving drug deli

289 Repurposing of ketamine for treating TRD provided a new understanding of the pat

290 antidepressant, has been approved by the FDA for treating treatment-resistant major depressive disord

291 been clinically adopted as an effective drug for treating type 2 diabetes (T2D), but its short circul

292 Metformin is the first-line therapy for treating type 2 diabetes and a promising anti-aging

293 HP-miR-802 pathway may present novel targets for treating type 2 diabetes and NAFLD.

294 e acetonide and the IDI were superior to PTA for treating uveitic ME with modest increases in the ris

295 pholipase A2 (PLA2) has long been considered for treating various diseases associated with an elevate

296 It is used in medication for treating various diseases like cancer, ulcers, tumor

297 l health and secretion as a potential target for treating vascular disease-associated skeletal muscle

298 Nucleotide analogues are used for treating viral infections such as HIV, hepatitis B,

299 505 mg L(-1)), demonstrating a robust system for treating wastewater of varying strengths.

300 tegies have been established in recent years for treating wide-necked bifurcation aneurysms, such as